SCHEMBL1978446

SCHEMBL1978446

Cc1ccc(S(=O)(=O)N2CCC(c3ccc(O)cc3O)CC2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.50
KDM4E B2RXH2 1/20 0.50
NPC1 O15118 1/20 0.50
RAB9A P51151 1/20 0.50
MEN1 O00255 1/20 0.49
KMT2A Q03164 1/20 0.49
LMNA P02545 2/20 0.49
PKM P14618 3/20 0.49
POLB P06746 1/20 0.49
HTT P42858 1/20 0.49
PTGDR2 Q9Y5Y4 1/20 0.48
TP53 P04637 1/20 0.48
MAPT P10636 1/20 0.48
MMP1 P03956 1/20 0.47
MMP2 P08253 1/20 0.47
MMP7 P09237 1/20 0.47
MMP9 P14780 1/20 0.47
MMP12 P39900 1/20 0.47
MMP14 P50281 1/20 0.47
MMP15 P51511 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1979757 0.93 ALDH1A1 (0.48) ALDH1A1KDM4ENPC1RAB9AMEN1
SCHEMBL14243695 0.82 PTGDR2 (0.52) ALDH1A1KDM4ENPC1RAB9AMEN1
SCHEMBL294854 0.81 USP5 (0.62) ALDH1A1KDM4ENPC1RAB9ALMNA
SCHEMBL5359944 0.76 ALDH1A1 (0.55) ALDH1A1KDM4EMEN1KMT2ALMNA
SCHEMBL5359940 0.76 ALDH1A1 (0.55) ALDH1A1KDM4EMEN1KMT2ALMNA
SCHEMBL5366806 0.76 ALDH1A1 (0.55) ALDH1A1KDM4EMEN1KMT2ALMNA
SCHEMBL4940237 0.74 ALDH1A1 (0.64) ALDH1A1KDM4ENPC1RAB9AMEN1
SCHEMBL17368685 0.74 CYP1A2 (0.59) MAPT
SCHEMBL1980422 0.73 NPC1 (0.45) NPC1LMNA
SCHEMBL266466 0.73 MEN1 (0.77) ALDH1A1KDM4ENPC1RAB9AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2509945-B1 4-(AZACYCLOALKYL)-BENZENE-1,3-DIOL DERIVATIVES AS TYROSINASE INHIBITORS AND THEIR SYNTHESIS AND USE THEREOF GALDERMA RES & DEV (FR) 2014-03-05 EP claimed
US-20120323012-A1 4-(AZACYCLOALKYL) -BENZENE-1,3-DIOL DERIVATIVES AS TYROSINASE INHIBITORS AND THEIR SYNTHESIS AND USE THEREOF GALDERMA RESEARCH & DEVELOPMENT (FR) 2012-12-20 US claimed
EP-2509945-A1 4- (AZACYCLOALKYL) -BENZENE-1, 3 -DIOL DERIVATIVES AS TYROSINASE INHIBITORS AND THEIR SYNTHESIS AND USE THEREOF Galderma Research & Development (FR) 2012-10-17 EP claimed
WO-2011070080-A1 4- (AZACYCLOALKYL) -BENZENE-1, 3 -DIOL DERIVATIVES AS TYROSINASE INHIBITORS AND THEIR SYNTHESIS AND USE THEREOF GALDERMA RESEARCH & DEVELOPMENT (FR) 2011-06-16 WO claimed
EP-2509945-B1 4-(AZACYCLOALKYL)-BENZENE-1,3-DIOL DERIVATIVES AS TYROSINASE INHIBITORS AND THEIR SYNTHESIS AND USE THEREOF GALDERMA RES & DEV (FR) 2014-03-05 EP disclosed
EP-2509945-B1 4-(AZACYCLOALKYL)-BENZENE-1,3-DIOL DERIVATIVES AS TYROSINASE INHIBITORS AND THEIR SYNTHESIS AND USE THEREOF GALDERMA RES & DEV (FR) 2014-03-05 EP disclosed
US-20120323012-A1 4-(AZACYCLOALKYL) -BENZENE-1,3-DIOL DERIVATIVES AS TYROSINASE INHIBITORS AND THEIR SYNTHESIS AND USE THEREOF GALDERMA RESEARCH & DEVELOPMENT (FR) 2012-12-20 US disclosed
US-20120323012-A1 4-(AZACYCLOALKYL) -BENZENE-1,3-DIOL DERIVATIVES AS TYROSINASE INHIBITORS AND THEIR SYNTHESIS AND USE THEREOF GALDERMA RESEARCH & DEVELOPMENT (FR) 2012-12-20 US disclosed
US-20120323012-A1 4-(AZACYCLOALKYL) -BENZENE-1,3-DIOL DERIVATIVES AS TYROSINASE INHIBITORS AND THEIR SYNTHESIS AND USE THEREOF GALDERMA RESEARCH & DEVELOPMENT (FR) 2012-12-20 US disclosed
EP-2509945-A1 4- (AZACYCLOALKYL) -BENZENE-1, 3 -DIOL DERIVATIVES AS TYROSINASE INHIBITORS AND THEIR SYNTHESIS AND USE THEREOF Galderma Research & Development (FR) 2012-10-17 EP disclosed
WO-2011070080-A1 4- (AZACYCLOALKYL) -BENZENE-1, 3 -DIOL DERIVATIVES AS TYROSINASE INHIBITORS AND THEIR SYNTHESIS AND USE THEREOF GALDERMA RESEARCH & DEVELOPMENT (FR) 2011-06-16 WO disclosed
WO-2011070080-A1 4- (AZACYCLOALKYL) -BENZENE-1, 3 -DIOL DERIVATIVES AS TYROSINASE INHIBITORS AND THEIR SYNTHESIS AND USE THEREOF GALDERMA RESEARCH & DEVELOPMENT (FR) 2011-06-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120323012-A1 4-(AZACYCLOALKYL) -BENZENE-1,3-DIOL DERIVATIVES AS TYROSINASE INHIBITORS AND THEIR SYNTHESIS AND USE THEREOF TYR, DDT, TH ALDH1A1 20/4885KDM4E 787/4885NPC1 2757/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.